UNSPSC 51351625: Estradiol monopalmitate

This classification denotes an estrogen C34H54O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1Q5Y448XT0, chemically known as estra-1,3,5(10)-triene-3,17-.beta.-diol 17-palmitate, but more generally known as estradiol monopalmitate, which bears US NIH Compound Identifier 111095. Most nations, for tariff and trade purposes, schedule estradiol monopalmitate under HS 29372300 and SITC 54153. As of Q4 2014, ESTRADIOL MONOPALMITATE remains US FDA's Preferred Term for this commodity.

Estradiol monopalmitate bears US NLM identifiers UMLS ID C2700019 and NCI Concept Code C76110. SMILES: CCCCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4C3CCC(C4)O)C.

UNSPSC 51351625 Estradiol monopalmitate is a Commodity code covering a specific pharmaceutical active ingredient supplied through state and local cooperative purchasing channels. Recent procurement activity under this code centers on establishing master agreements for multi-source generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers to state agencies, local government facilities, and participating healthcare systems. Vendors supply pharmaceutical manufacturers' products identified by National Drug Code (NDC), maintaining compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA). State and local health departments, correctional facilities, hospital systems, and other agency healthcare operations source these products through cooperative purchasing agreements that establish pricing, supply chain relationships with authorized pharmaceutical wholesalers, and delivery timelines. The issuing body model is predominantly multi-state cooperative purchasing alliances—entities like the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) that aggregate demand across multiple state agencies and local government participants to negotiate volume pricing and standardized terms.

The Minnesota Department of Administration's Office of State Procurement, administering MMCAP on behalf of participating state and local entities including Oregon, issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products effective July 1, 2026. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health 110/112, Morris & Dickson), certify product availability by May 15, 2026, and offer flexible pricing structures including flat price, net price (NF30/NF60/NF90), or WAC-minus formats. Evaluation weighs price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance (EDI capability, administrative fee agreement, data format requirements) at 15 percent combined. Vendors pay a 3 percent administrative fee on all contract purchases and face performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines. Contract terms span two years for new responders with optional MMCAP extensions, while incumbent vendors' terms align with existing agreement expiration dates through June 30, 2028.